Eaton Corporation plc vs IDEXX Laboratories, Inc. — how do they compare? Eaton Corporation plc trades at $458.2 (market cap $172.82B), while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: Eaton Corporation plc is far larger — about 3.7× IDEXX Laboratories, Inc.'s market cap, and Eaton Corporation plc pays a 0.99% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ETN | IDXX | |
|---|---|---|
Market Cap | $172.82B | $46.22B |
Sector | Technology | Health |
52-Week High | $459.29 | $766.68 |
52-Week Low | $315.82 | $526.44 |
Enterprise Value | $193.45B | $47.12B |
Dividend Yield | 0.99% | — |
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $459.96, up 3.37% with strong technical momentum and bullish moving average signals. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.15 beating expectations of $3.07. Revenue growth continues with 2026 projections at $30.0 billion, though net profit margin is expected to compress to 12.75%. Recent news highlights Eaton's $7 million Air Force contract for quantum computing grid security and strong AI infrastructure demand.
Outlook remains positive with analyst consensus price target of $499.75 (8.6% upside) and unanimous bullish ratings (26 Buy, 0 Sell). Key risks include premium valuation (P/E 45.31) and execution challenges in meeting raised 2026 guidance. The stock's proximity to 52-week highs suggests near-term consolidation potential despite strong fundamental momentum.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →